Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG’s Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production.
Most people with chronic myeloid leukemia (CML) have a genetic mutation, called the Philadelphia chromosome, which causes the bone marrow to make an enzyme that triggers the development of abnormal and unhealthy white blood cells.
Source: Reuters
Filed Under: Drug Discovery
